My point is that with a molecule like leronlimab,

Quote:

---

My point is that with a molecule like leronlimab, we could do much better in the partnering department.

---

Any larger pharma would want to take over distribution of all indications. If they gave us 30% I would surprised, then subtract the royalties. Leaving hundreds of billions of dollars on the table is not a wise move.